– Entered collaboration with Pfizer to evaluate triplet combination of STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; trial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...

Investigator-assessed PFS improved with atirmociclib plus fulvestrant versus fulvestrant alone or everolimus/exemestane, achieving HR 0.60 and meeting the primary endpoint with clinically meaningful ...

Pfizer said a mid-stage study of its investigational CDK4 inhibitor atirmociclib met its key goal in certain patients with breast cancer. Pfizer on Tuesday said the randomized Phase 2 study met its ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting a Phase 1 ...

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...